Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 6/20 | 0.38 |
| ▸ | NAAA | Q02083 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11139629 | 0.83 | ACHE (0.33) | — | |
| SCHEMBL20146 | 0.83 | MIF (0.40) | MIFTSHR | |
| SCHEMBL165792 | 0.83 | MIF (0.40) | MIFTSHR | |
| SCHEMBL28219540 | 0.82 | MIF (0.36) | MIFNAAAMAOAMAOBKEAP1 | |
| SCHEMBL27749125 | 0.81 | MIF (0.39) | MIFTSHR | |
| SCHEMBL8434594 | 0.80 | NAAA (0.33) | MIFNAAAMAOAMAOBKEAP1 | |
| SCHEMBL22444765 | 0.78 | RIPK1 (0.42) | MIFNAAA | |
| SCHEMBL22444522 | 0.78 | RIPK1 (0.42) | MIFNAAA | |
| SCHEMBL22444535 | 0.78 | RIPK1 (0.42) | MIFNAAA | |
| SCHEMBL22444457 | 0.78 | RIPK1 (0.42) | MIFNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722230-B2 | Polyurethane binder, electrodes containing the same and lithium battery employing the electrodes | SAMSUNG SDI CO., LTD. (KR) | 2014-05-13 | — | — | US | claimed |
| EP-1690902-B1 | Surface-modified nanoparticles, method for making them and use | BYK CHEMIE GMBH (DE) | 2012-08-15 | — | — | EP | disclosed |
| US-20110082151-A1 | SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| EP-1690902-A2 | Surface-modified nanoparticles, method for making them and use | Byk-Chemie GmbH (DE) | 2006-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082151-A1 | SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR | EDNRA, EDNRB, GLP1R | MIF 3317/4885NAAA 2234/4885MAOA 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.